#1 Clinical Trials Search in Europe

7-FLUORO-3-METHYL-8-[6-(3-PIPERIDIN-1-YLPROPOXY)PYRIDIN-3-YL]-1-PROPAN-2-YLIMIDAZO[4,5-C]QUINOLIN-2-ONE

Clinical trials are investigating 7-FLUORO-3-METHYL-8-[6-(3-PIPERIDIN-1-YLPROPOXY)PYRIDIN-3-YL]-1-PROPAN-2-YLIMIDAZO[4,5-C]QUINOLIN-2-ONE in people with glioblastoma. The trial data focus on studying treatment benefit, especially overall survival, and on finding patient groups or biomarkers that may respond better. The main target population is patients with newly diagnosed or recurrent glioblastoma.

Table of Contents

Trial overview

The available trial data describe one interventional study in glioblastoma, a type of brain cancer.[1] The study is authorised and planned for 1845 participants.[1]

This trial is designed to test multiple treatment regimens and to see whether any of them improve patient outcomes in newly diagnosed and recurrent glioblastoma.[1]

Who is being studied

The target population includes people with glioblastoma (GBM), including those who are newly diagnosed and those whose disease has returned.[1] The source data do not list detailed age limits, lab requirements, or other eligibility rules.[1]

In simple terms, this means the study is focused on patients with a serious brain tumor, not on healthy volunteers.[1]

Study design and phase

The study is listed as Phase 4, which usually means the treatment is being studied in a larger real-world patient group after earlier research stages.[1] The trial also uses a screening stage and an expansion stage.[1]

In the screening stage, researchers look for experimental therapies that may improve overall survival.[1] In the expansion stage, they confirm the most promising therapies and the biomarker patterns linked with benefit.[1]

Treatments and comparisons

The trial data list several study drugs: ADI-PEG-20, Troriluzole, and AZD1390.[1] These are being tested as part of multiple regimens, meaning different treatment plans are being compared within the study.[1]

The source does not provide a full description of all study groups or how each regimen is assigned, so only the listed trial information can be confirmed.[1]

Main endpoint and what it means

The primary endpoint is overall survival, defined as the time from randomization until death from any cause.[1] This is one of the most important measures in cancer trials because it shows whether a treatment helps patients live longer.[1]

Randomization means patients are assigned to a study group by chance, which helps make the groups more fair for comparison.[1]

Biomarkers and patient subgroups

The study aims to identify patient subtypes or biomarkers that may be linked to better benefit from treatment.[1] A biomarker is a measurable sign in the body that may help researchers understand disease behavior or treatment response.[1]

This means the study is not only asking whether a treatment works, but also which patients may be most likely to benefit.[1]

Trial summary

In summary, the trial data for 7-FLUORO-3-METHYL-8-[6-(3-PIPERIDIN-1-YLPROPOXY)PYRIDIN-3-YL]-1-PROPAN-2-YLIMIDAZO[4,5-C]QUINOLIN-2-ONE are centered on glioblastoma research.[1] The study is authorised, Phase 4, and planned for a large group of 1845 patients.[1] Its main goal is to improve overall survival and to confirm which patient groups and biomarkers are linked to benefit.[1]

Trial ID Phase Condition studied Status Enrollment
NCT03970447 Phase 4 Glioblastoma (newly diagnosed and recurrent) Authorised 1845

FAQ

  • What condition is being studied in these trials? The trials are studying glioblastoma, which is a type of brain cancer. The data include both newly diagnosed and recurrent cases.
  • Who may take part in the trial? The trial is aimed at patients with glioblastoma. The source data mention newly diagnosed and recurrent patients, but do not list detailed eligibility rules.
  • What is the main goal of the study? The main goal is to see whether experimental therapies improve overall survival. Overall survival means how long patients live after randomization, which is the process of being assigned to a study group by chance.
  • What phase is this trial? This study is listed as Phase 4. Phase 4 trials usually look at how a treatment performs in larger patient groups after earlier testing.
  • What else is the trial trying to learn? The study also looks for patient subtypes and biomarkers that may help predict who benefits most. Biomarkers are measurable signs in the body that can help guide research.

Ongoing Clinical Trials on 7-FLUORO-3-METHYL-8-[6-(3-PIPERIDIN-1-YLPROPOXY)PYRIDIN-3-YL]-1-PROPAN-2-YLIMIDAZO[4,5-C]QUINOLIN-2-ONE

  • Study of Troriluzole and ADI-PEG-20 for Patients with Newly Diagnosed and Recurrent Glioblastoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany

Glossary

  • Glioblastoma (GBM): A fast-growing type of brain cancer. It can be newly diagnosed or come back after treatment.
  • Newly diagnosed: A condition that has been found for the first time.
  • Recurrent: A disease that has returned after treatment.
  • Interventional study: A clinical trial where researchers give a treatment or compare treatments to study outcomes.
  • Phase 4: A later stage of clinical research that studies a treatment in a larger group of patients.
  • Randomization: Assigning patients to a study group by chance.
  • Overall survival: The length of time from the start of a study point, such as randomization, until death from any cause.
  • Biomarker: A measurable sign in the body that may help show how a disease is behaving or who may respond to treatment.
  • Patient subtype: A smaller group of patients with shared features, such as a similar disease pattern or biomarker.
  • Expansion stage: A later part of a study that confirms earlier findings in more patients.

References